Literature DB >> 9283505

Prediction of compliance with outpatient referral in patients with schizophrenia and psychoactive substance use disorders.

C R Miner1, R N Rosenthal, D J Hellerstein, L R Muenz.   

Abstract

BACKGROUND: Most patients with concurrent schizophrenia and psychoactive substance use disorders may be adequately treated as outpatients. However, many do not comply with outpatient referrals and are therefore at heightened risk for rehospitalization.
METHOD: Drawing on standardized interview data collected during an index hospitalization, we developed a logistic regression model to predict compliance with outpatient treatment. The model was tested on a confirmatory sample, and its sensitivity and specificity were further evaluated in a cross-validation study of 1000 random samples.
RESULTS: In a reference sample, the logistic function distinguished compliant from noncompliant patients in 37 (76%) of 49 cases. In a confirmatory sample, compliance status was predicted for 11 (78%) of 14 patients with a sensitivity of 1.00 and a specificity of 0.67. Women and patients with negative syndrome schizophrenia were compliant with outpatient referral, whereas those with mixed syndromes were most likely to be noncompliant. Cross-validation supports the stability of the model.
CONCLUSION: While most persons with schizophrenia and concurrent substance abuse comply with integrated outpatient treatment, most who cannot may be predicted in advance.

Entities:  

Mesh:

Year:  1997        PMID: 9283505     DOI: 10.1001/archpsyc.1997.01830200030005

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  10 in total

1.  A family intervention program for dual disorders.

Authors:  Kim T Mueser; Lindy Fox
Journal:  Community Ment Health J       Date:  2002-06

2.  Drug-abusing offenders with comorbid mental disorders: problem severity, treatment participation, and recidivism.

Authors:  Adi Jaffe; Jiang Du; David Huang; Yih-Ing Hser
Journal:  J Subst Abuse Treat       Date:  2012-02-02

3.  Integrating services for schizophrenia and substance abuse.

Authors:  D J Hellerstein; R N Rosenthal; C R Miner
Journal:  Psychiatr Q       Date:  2001

4.  Predictors of initiation and engagement in substance abuse treatment among individuals with co-occurring serious mental illness and substance use disorders.

Authors:  Clayton H Brown; Melanie E Bennett; Lan Li; Alan S Bellack
Journal:  Addict Behav       Date:  2010-12-10       Impact factor: 3.913

5.  Clinical characteristics and service utilization patterns of clients with schizophrenia-spectrum disorders in public residential detoxification settings.

Authors:  Jennifer Alvidrez; Barbara E Havassy
Journal:  Community Ment Health J       Date:  2006-04

6.  Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders.

Authors:  Birgit Janssen; Wolfgang Gaebel; Martin Haerter; F Komaharadi; Birgit Lindel; Stefan Weinmann
Journal:  Psychopharmacology (Berl)       Date:  2006-05-19       Impact factor: 4.530

7.  Predictors of smoking cessation group treatment engagement among veterans with serious mental illness.

Authors:  Letitia E Travaglini; Lan Li; Clayton H Brown; Melanie E Bennett
Journal:  Addict Behav       Date:  2017-07-10       Impact factor: 3.913

Review 8.  Disengagement from mental health services. A literature review.

Authors:  Aileen O'Brien; Rana Fahmy; Swaran P Singh
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-11-26       Impact factor: 4.328

9.  How do resource dependencies affect treatment practices? The case of outpatient substance abuse treatment programs.

Authors:  Jeffrey A Alexander; Rebecca Wells
Journal:  Med Care Res Rev       Date:  2008-07-24       Impact factor: 3.929

10.  Needs-oriented discharge planning and monitoring for high utilisers of psychiatric services (NODPAM): design and methods.

Authors:  Bernd Puschner; Sabine Steffen; Wolfgang Gaebel; Harald Freyberger; Helmfried E Klein; Tilman Steinert; Rainer Muche; Thomas Becker
Journal:  BMC Health Serv Res       Date:  2008-07-21       Impact factor: 2.655

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.